HCAT insiders were on both sides of the trade this year. Buys came to roughly $106,000 (one buyer), sales to $201,000 (two sellers).
Kohl Simeon (CEO) made the biggest buy, worth around $106,000. Notably, at least one C-suite executive was among the buyers.
On the institutional side, 127 funds reported holding HCAT at the end of Q2 2026, and more funds sold than bought. Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 16, 2026 | Kohl Simeon | CEO | Buy | 59,000 | $1.79 | $106K | SEC |
| Dec 9, 2025 | Landry Benjamin | Executive Officer | Sell | 27,425 | $2.64 | $72K | SEC |
| Dec 9, 2025 | Larson-Green Julie | Director | Sell | 47,997 | $2.67 | $128K | SEC |
| Sep 9, 2025 | Landry Benjamin | Executive Officer | Sell | 6,175 | $3.35 | $21K | SEC |
| Jun 9, 2025 | Landry Benjamin | Executive Officer | Sell | 6,057 | $3.94 | $24K | SEC |
| May 7, 2025 | LeSueur Daniel | COO | Sell | 5,209 | $4.10 | $21K | SEC |
| Apr 7, 2025 | LeSueur Daniel | COO | Sell | 5,209 | $4.15 | $22K | SEC |
| Mar 10, 2025 | Landry Benjamin | Executive Officer | Sell | 13,827 | $4.55 | $63K | SEC |
| Mar 10, 2025 | LeSueur Daniel | COO | Sell | 16,902 | $4.52 | $76K | SEC |
| Feb 20, 2025 | Llewelyn Linda | Executive Officer | Sell | 6,441 | $5.43 | $35K | SEC |
| Feb 6, 2025 | LeSueur Daniel | COO | Sell | 5,209 | $5.76 | $30K | SEC |
| Jan 17, 2025 | Llewelyn Linda | Executive Officer | Sell | 6,442 | $5.80 | $37K | SEC |
| Jan 10, 2025 | LeSueur Daniel | COO | Sell | 5,209 | $7.51 | $39K | SEC |
| Jan 10, 2025 | Landry Benjamin | Executive Officer | Sell | 2,500 | $7.52 | $19K | SEC |
| Jan 2, 2025 | Gallagher Duncan | Director | Sell | 4,500 | $6.93 | $31K | SEC |
In the last 12 months Health Catalyst, Inc. insiders made open-market purchases worth about $106,000 and sales worth about $201,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in HCAT was filed on 2026-09-16.
127 investment managers reported holding HCAT in SEC Form 13F filings for Q2 2026.
No congressional trades in HCAT were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).